For patients with AMI without heart failure, such as in the REMINDER trial (Montalescot et al., 2014), ALBATROSS trial (Beygui et al., 2016) and MINIMIZE STEMI trial (Bulluck et al., 2019), the application of MRA reduced BNP levels, mortality, and size of ST-segment elevation myocardial infarction. The gene discussed is NPPB; the disease is heart failure.